Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial.

Background: Understanding how asthma biomarkers relate to gene expression signatures could help identify drivers of pathogenesis.

Objective: This post hoc exploratory analysis of the phase II tralokinumab trial MESOS (ClinicalTrials.gov identifier NCT02449473) aimed to profile baseline airway inflammation in patients with moderate-to-severe asthma.